IDO-Independent Suppression of T Cell Effector Function by IFN-γ–Licensed Human Mesenchymal Stromal Cells
The DOI matches its Crossref record; 63 of the 63 references it cites were found in a registry or an index.
Abstract
Human bone marrow–derived mesenchymal stromal cells (MSCs) inhibit proliferation of activated T cells, and IFN-γ plays an important role in this process. This IFN-γ–licensed veto property is IDO-dependent. To further decipher the mechanistic underpinnings of MSC veto function on T cells, we investigated the effect of MSCs and IFN-γ–licensed MSCs on T cell effector function as assayed by cytokine secretion of T cells. Although MSCs and IFN-γ–licensed MSCs inhibit T cell proliferation, only IFN-γ–licensed MSCs significantly inhibit Th1 cytokine (IFN-γ, TNF-α, and IL-2) production by T cells. Additionally, IFN-γ–licensed MSCs inhibit T cell degranulation as well as single, double, and triple cytokine–producing T cells. Although IFN-γ–licensed MSCs upregulate their IDO activity, we found that MSC IDO catalytic function is dispensable with regard to MSC-driven inhibition of T cell effector function. Novel flow cytometry based functional screening of MSC-expressed, IFN-γ–licensed inhibitory molecules identified B7H1 and B7DC/PD1 pathways as essential effectors in blocking T cell function. Small interfering RNA–mediated blocking of B7H1 and B7DC reverses the inhibitory potential of IFN-γ–licensed MSCs on T cell effector function. Mechanistic analysis revealed that clustering of MHC and coinhibitory molecules are indispensable for the inhibitory effect of IFN-γ MSCs. Although exogenous IL-2 reverses B7H1-Ig–mediated inhibition of T cell proliferation, it does not affect the veto function of IFN-γ MSCs on both T cell proliferation and effector function. Our results reveal a new immunosuppressive property of IFN-γ–licensed MSCs that inhibits T cell effector function independent of IDO but through the ligands for PD1.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A study by Chinnadurai et al. elegantly showed that MSCs can inhibit PBMC proliferation through PD1/PD-L1 [48].”
In the citing paper
“IFN-γ-primed MSCs have demonstrated to block T cell proliferation in a dose-dependent manner and to abrogate the production of IFN-γ, IL-2 and TNF-α, three cytokines with a role in T cell-derived immune response [136].”
From Mesenchymal stem cell secretome for regenerative medicine: Where do we stand? (2025) · cites this paper as [136]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“M arrowmesenchymal stromal cells (MSCs) play a role in maintaining the hematopoietic niche, regulate marrow immune homeostasis, and can differentiate into bone, cartilage, and adipocytes as a mesenchymal progenitor pool (1, 2).”
BackgroundMesenchymal stem cells in health and disease
Uccelli, A., Moretta, L., & Pistoia, V. (2008) · Nature Reviews Immunology · doi:10.1038/nri2395 · Cited by 3,746 · cited 1×
“The therapeutic potential of transfused MSCs has been demonstrated in animal models of experimental autoimmune encephalitis, diabetes, rheumatoid arthritis, myocardial infarction, acute lung injury, retinal degeneration, acute renal failure, and transplant rejection (9, 10).”
BackgroundDi Nicola, M., Carlo-Stella, C., Magni, M., Milanesi, M., Longoni, P. D., Matteucci, P., Grisanti, S., & Gianni, A. M. (2002) · Blood · doi:10.1182/blood.v99.10.3838 · Cited by 3,226 · cited 1×
“Therefore, an analysis of MSC immune plasticity in response to exogenous IFN-g stimulation (6, 22) and how this serves as an immune checkpoint to T cell activity are of physiological and translational interest.”
MethodCentral Memory and Effector Memory T Cell Subsets: Function, Generation, and Maintenance
Sallusto, F., Geginat, J., & Lanzavecchia, A. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104702 · Cited by 3,067 · cited 1×
“Once naive T cells are exposed to an activation signal they proliferate, and a subset becomes effector T cells as manifested by cytokine secretion and degranulation, based on their memory status (23, 24).”
BackgroundLe Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734 · cited 1×
“In human phase II clinical trials, MSCs were shown to be effective in treating graft-versus-host disease (11), although study of an industrial MSC product in a phase III trial was negative (12–14).”
BackgroundFriedenstein, A. J., Chailakhjan, R. K., & Lalykina, K. S. (1970) · Cell Proliferation · doi:10.1111/j.1365-2184.1970.tb00347.x · Cited by 2,724 · cited 1×
“Although endogenous clonogenic marrow MSCs represent a small minority of all nucleated cells in marrow space, typically 1:100,000, these same cells possess a robust mitogenic potential when cultured ex vivo (3, 4).”
BackgroundThe Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity
Zhu, C., Anderson, A. C., Schubart, A., Xiong, H., Imitola, J., Khoury, S. J., Zheng, X. X., Strom, T. B., & Kuchroo, V. K. (2005) · Nature Immunology · doi:10.1038/ni1271 · Cited by 2,057 · cited 1×
“We specifically examined the correlation between MSC licensing and T cell cytokine suppression with MSC expression of galectin-9 (34), TRAIL (35), HLAG (36), TNFR (37), SLAM2 (38), HLAC (39), OX40L (40), CD200R (41), FASL (42), and B7H1/B7DC (26).”
BackgroundHeterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues.
Friedenstein, A. J., Kv, P., KUROLESOVA, A. I., & Frolova, G. P. (1968) · PubMed · Cited by 1,921
HETEROTOPIC TRANSPLANTS OF BONE MARROW
FRIEDENSTEIN, A. J., PETRAKOVA, K. V., KUROLESOVA, A. I., & FROLOVA, G. P. (1968) · Transplantation · doi:10.1097/00007890-196803000-00009 · Cited by 1,699
Meisel, R., Zibert, A., Laryea, M., Göbel, U., Däubener, W., & Dilloo, D. (2004) · Blood · doi:10.1182/blood-2003-11-3909 · Cited by 1,646
Research works printed but not linked: 1
- Jeremias, 1998, TRAIL/Apo-2-ligand-induced apoptosis in human T cells, Eur. J. Immunol., 28, 143, 10.1002/(SICI)1521-4141(199801)28:01<143::AID-IMMU143>3.0.CO;2-3 · DOI · Paper page
Cited by
Items 201–267 of 267
Mante, N., Undale, V., Sanap, A. P., Bhonde, R. R., Tambe, P., Bansode, M., & Gupta, R. K. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.114701 · Cited by 9
Ke, M., Liu, W., Lu, H., Pan, X., Wu, M., Qi, N., Wang, Z., Wu, Y., & Zhang, F. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1613502 · Cited by 8
Ahmadifard, R., Jafarzadeh, A., Mahmoodi, M., Nemati, M., Rahmani, M., Khorramdelazad, H., & Ayoobi, F. (2023) · Drug Research · doi:10.1055/a-1995-6365 · Cited by 6
“However, it was previously indicated that the IFN-γ-exposed MSCs displayed greater expression of IDO compared to control MSCs [53, 59, 60].”
ResultLiu, C., Kang, L., Chen, F., Mu, D., Shen, S., Wang, K., Hu, J., Xie, J., & Xu, B. (2020) · Stem Cells and Development · doi:10.1089/scd.2019.0264 · Cited by 9
Ruxolitinib Inhibits IFNγ Licensing of Human Bone Marrow Derived Mesenchymal Stromal Cells
Ryan, M. M., Patel, M., Hogan, K., Lipat, A. J., Scandolara, R., Das, R., Bruker, C., Galipeau, J., & Chinnadurai, R. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.02.002 · Cited by 6
Self-citationKoch, D. W., & Schnabel, L. V. (2023) · American Journal of Veterinary Research · doi:10.2460/ajvr.23.07.0154 · Cited by 6
“37,38 41 Additionally, these cells contain the ability to secrete tumor necrosis factor-inducible gene 6, responsible for the promotion of FoxP3+ Treg cells.”
BackgroundMSC-Based Cell Therapy for COVID-19-Associated ARDS and Classical ARDS: Comparative Perspectives
Weiss, D. J., & Enes, S. R. (2023) · Current Stem Cell Reports · doi:10.1007/s40778-023-00231-6 · Cited by 6
“For example, IFN-γ pre-treated MSCs have been demonstrated to inhibit T-cell proliferation as well as inhibit T-cell production of IFN-γ, TNF-α, and IL-2 in vitro [46].”
Gil-Chinchilla, J. I., Bueno, C., Martínez, C. M., Ferrández-Múrtula, A., García-Hernández, A. M., Blanquer, M., Molina-Molina, M., Zapata, A. G., Sackstein, R., Moraleda, J. M., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1385691 · Cited by 6
Hu, M., Zhang, C., Liu, J., Chen, Y., Kang, J., Zhong, J., Lin, S., Liang, Y., Cen, R., Zhu, X., et al. (2024) · Stem Cell Research & Therapy · doi:10.1186/s13287-024-04023-5 · Cited by 7
Truong, N. C., Phan, T. N. M., Huynh, N. T., Pham, K. D., & Pham, P. V. (2023) · Advances in experimental medicine and biology · doi:10.1007/5584_2023_776 · Cited by 6
Impact of platelet lysate on immunoregulatory characteristics of equine mesenchymal stromal cells
Moellerberndt, J., Niebert, S., Fey, K., Hagen, A., & Burk, J. (2024) · Frontiers in Veterinary Science · doi:10.3389/fvets.2024.1385395 · Cited by 4
Hu, W., Yang, G., Ao, L., Shen, P.-X., Yao, M., Yuan, Y., Long, J., Li, Z., & Xu, X. M. (2025) · Chinese Journal of Traumatology · doi:10.1016/j.cjtee.2025.04.003 · Cited by 5
Rossello-Gelabert, M., Heras, K. L., Gonzalez‐Pujana, A., Igartua, M., Santos‐Vizcaíno, E., & Hernández, R. M. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04775-8 · Cited by 6
“…widely reported to maximize synergistic activation of JAK/STAT1 and NF-κB while avoiding cytotoxicity, and consistently associated with the upregulation of soluble anti-inflammatory mediators under preserved viability [45, 47–50], thereby supporting both reproducibility and translational relevance.”
Ogawa, T., Kajiya, M., Horikoshi, S., Yoshii, H., Yoshino, M., Motoike, S., Morimoto, S., Sone, H., Iwata, T., Ouhara, K., et al. (2022) · Regenerative Therapy · doi:10.1016/j.reth.2022.04.003 · Cited by 4
“Otherwise, IFN-g treatment up-regulates programmed cell death ligand 1 (PD-L1), which binds to programmed cell death 1 (PD-1) in immune cells to attenuate their activity [32].”
BackgroundCastro-Manrreza, M. E., Romano, L. E., López-García, L., Contreras, O. M., & Montesinos, J. J. (2025) · Stem Cells and Development · doi:10.1089/scd.2025.0064 · Cited by 5
Zhang, Z., Wilson, N. A., Chinnadurai, R., Panzer, S. E., Redfield, R. R., Reese, S. R., Galipeau, J., & Djamali, A. (2018) · Transplantation Direct · doi:10.1097/txd.0000000000000827 · Cited by 6
Self-citationImmunomodulatory Properties of Dental-Derived Mesenchymal Stem Cells
Andrukhov, O., Behm, C., Blufstein, A., & Rausch‐Fan, X. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.78049 · Cited by 5
Blocking antibody-mediated phosphatidylserine enhances cancer immunotherapy
Zhang, J., Dai, Z., Yan, C., Wang, D., & Tang, D. (2021) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-021-03792-3 · Cited by 3
ShamsEldeen, A. M., Hosny, S. A., Maghib, K., & Ashour, H. (2025) · World Journal of Stem Cells · doi:10.4252/wjsc.v17.i8.107480 · Cited by 3
Tumangelova-Yuzeir, K. D., Minkin, K., Ангелов, И., Ivanova‐Todorova, E., Kurteva, E. K., Vasilev, G., Arabadjiev, J. I., Karazapryanov, P., Gabrovski, K., Zaharieva, L., et al. (2023) · Current Issues in Molecular Biology · doi:10.3390/cimb45030169 · Cited by 3
“It is known that, induced by INFγ, MSCs increase the expression of this molecule and also succeed in inhibiting both the proliferation of T cells and their effector functions [62].”
BackgroundCalcat-i-Cervera, S., Rendra, E., Scaccia, E., Amadeo, F., Hanson, V., Wilm, B., Murray, P. A., O’Brien, T., Taylor, A., & Bieback, K. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.09.14.507944 · Cited by 3
Jo, C., Lee, S.-Y., Son, Y., Lee, H., Lee, H.-J., Oh, S.-J., Hong, C., Choe, Y., & Lee, S. (2025) · Stem Cells · doi:10.1093/stmcls/sxaf044 · Cited by 3
Low dose IFNγ remodels enhancer landscape to potentiate mesenchymal stromal cell activation
Lin, J., Ruan, D., Hu, Q., Cao, X., Zhou, W., & Hu, S. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04801-9 · Cited by 3
“IFNγ primes MSCs by upregulating the expression of various soluble and membrane-bound molecules, such as indoleamine 2,3-dioxy-genase (IDO) and programmed death-ligand 1 (PD-L1), which play crucial roles in suppressing cytotoxic T-cell responses [7–9].”
Pérez, J. A. V., Parcero, J. J., Moreno, R. C., Cuevas, L. I. G., Lopez, J. J., Ichim, T. E., McGreevy, K. M., Lin, F., Kesari, S., & Datta, S. (2023) · Cureus · doi:10.7759/cureus.44110 · Cited by 2
“It has been previously reported that umbilical cord-derived mesenchymal stem cells have therapeutic efficacy in a model of acute lung injury induced by influenza A (H5N1) virus [21].”
BackgroundHuman cornea-derived mesenchymal stromal cells inhibit T cells through indoleamine 2,3 dioxygenase
Faircloth, T. U., Temple, S., Parr, R. N., Soma, A., Massoumi, H., Jalilian, E., Djalilian, A. R., Hematti, P., Rajan, D., & Chinnadurai, R. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.01.009 · Cited by 3
Self-citationPochon, C., Perouf, R., Notarantonio, A., Bertrand, A., Charif, N., Bittencourt, M. D. C., Fouquet, G., Cauchois, G., Bensoussan, D., Moulin, D., et al. (2025) · Current Research in Translational Medicine · doi:10.1016/j.retram.2025.103543 · Cited by 3
Wang, T., Li, Y., Tian, J., Sun, G., Yang, T., Meng, Z., Li, W., Su, X., Liu, R., Gong, P., et al. (2025) · Stem Cell Research & Therapy · doi:10.1186/s13287-025-04663-1 · Cited by 1
Goss, K. L., Grant, M., Guglani, L., Miller, H. J., Woods, E. J., Caldwell, C., Fitzpatrick, A. M., & Horwitz, E. M. (2025) · Cytotherapy · doi:10.1016/j.jcyt.2025.07.008 · Cited by 1
Chinnadurai, R., & Galipeau, J. (2014) · Inflammation and Regeneration · doi:10.2492/inflammregen.34.168 · Cited by 1
Self-citationZhang, S., Ren, J.-Y., & Yang, B. (2021) · World Journal of Stem Cells · doi:10.4252/wjsc.v13.i11.1628 · Cited by 2
Alivernini, S., Masserdotti, A., Magatti, M., Cargnoni, A., Papait, A., Silini, A. R., Romoli, J., Ficai, S., Mario, C. D., Gremese, E., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e41438 · Cited by 3
“In the same co-culture condition, the authors also observed the enhanced secretion of IDO, hepatocyte growth factor (HGF) and IL-10, which are factors known to be secreted by hUC-MSC and thus could potentially be involved in CDH11 downregulation [77,78].”
Reconciling the stem cell and paracrine paradigms of mesenchymal stem cell function
Boregowda, S. V., & Phinney, D. G. (2016) · Wiley eBooks · doi:10.1002/9781118907474.ch64 · Cited by 1
Mesenchymal stromal cells for the treatment of autoimmune diseases
Lewis, C. N., & Galipeau, J. (2016) · Wiley eBooks · doi:10.1002/9781118907474.ch54 · Cited by 1
Self-citationda Silva, R. O. (2021) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.9.2021.tde-20122021-134008 · Cited by 1
Amino acid metabolism in the inflammatory niche
Wang, A. C.-Y. (2015) · Spiral (Imperial College London) · doi:10.25560/28572
“called B7-H1, has been shown to be induced by IFN-γ and participate in T-cell suppression via cell contact [171, 172].”
BackgroundThe Inflammatory Environment and Its Effects on Mesenchymal Stem/Stromal Cells
Németh, K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803102-5.00018-5
The Immune Response to the Allograft
Carty, F., & English, K. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-801734-0.00018-7
A Study of Immune Function Improvement Induced by Ganoderma Lucidum Alkaloid in Mice
Cheng, L., Xie, X., & Yu, T. (2018) · International Conference on Bioscience, Biochemistry and Bioinformatics (ICBBB) · doi:10.1145/3180382.3180407
“[9, 10]; increase of levels of IFN-γ indicates our body have strong immunity.”
BackgroundKay, A. G., Fox, J. M., Hewitson, J. P., Stone, A. P., Robertson, S., James, S. R., Wang, X., Kapasa, E., Yang, X., & Genever, P. G. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.02.10.479972
Role of Mesenchymal Stem/Stromal Cells in Cancer Development
Castro-Manrreza, M. E., & Martínez, I. (2023) · Interdisciplinary cancer research · doi:10.1007/16833_2022_103
许, 雪. (2023) · Advances in Clinical Medicine · doi:10.12677/acm.2023.133702
Survey to Assess the Impact of the COVID-19 Pandemic on Tinnitus Perception
Yılmaz, O., Yaman, H., Mutlu, B. Ö., Bayazıt, D., Eti, S., Demirhan, H., & Bayazit, Y. A. (2024) · Gazi Medical Journal · doi:10.12996/gmj.2023.3726
Neo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24164987
Neo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24164990
Balusu, R., Soder, R. P., Dudley, N. R., McGuirk, J. P., & Abhyankar, S. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.07.027
Larsen, M. C., Gurevic, I., Berube, L., Loo, A. V., Hanson, E., Adam, R. J., Manfrè, V., Parker, M. H., Paz, C., Galipeau, J., et al. (2025) · Regenerative Therapy · doi:10.1016/j.reth.2025.11.004 · Cited by 2
“…surrogate markers of MSC immunomodulatory effects, IDO, PD-L1, and ICAM-1 were clearly optimized in the IFN γ and TNF α condition over the IFN γ alone [10,63]; yet, there was no clear difference between IFN γ alone and combined IFN γ and TNF α regarding ability to suppress T-cell proliferation.”
Self-citationCalcat-i-Cervera, S., Rendra, E., Scaccia, E., Amadeo, F., Hanson, V., Wilm, B., Murray, P., O’Brien, T., Taylor, A., & Bieback, K. (2023) · Figshare · doi:10.6084/m9.figshare.22767212
Neo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24164972
Neo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24164984
Neo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24164975
Neo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24164969
Neo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24164978
Akhter, W., Nakhle, J., Vaillant, L., Garcin, G., Saout, C. L., Simon, M., Crozet, C., Djouad, F., Jørgensen, C., Vignais, M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22598849
Neo, S. H., Her, Z., Othman, R. B., Tee, C. A., Ong, L. C., Wang, Y., Tan, I., Tan, J., Yang, Y., Yang, Z., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24164966
Mesenchymal stromal cell therapy in haematology: from laboratory to clinic and back again.
Becker, A. D. (2015) · VUBIR (Vrije Universiteit Brussel)
Liao, D., Wen, J., Ritter, T., & Wang, J. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-07947-z
“These cytokines induce a robust immunomodulatory phenotype in MSCs, marked by the upregulation of key mediators like indoleamine 2,3-dioxygenase (IDO) [11, 14, 22] and programmed death-ligand 1 (PD-L1) [22–24].”
Low oxygen preconditioning of umbilical cord MSCs: from biological to mechanistic innovation
Hazeri, M., Zaman, W. S. W. K., Rezaei, M. A., Hafez, P., Yee, T. X., Keflee, R. D., Hussin, H. M., & Rahman, M. A. B. A. (2026) · Journal of Translational Medicine · doi:10.1186/s12967-026-08026-z · Cited by 1
“Given the growing interest in cell-free therapeutics, hypoxia-induced modification of the MSC secretome may offer safer and more scalable therapeutic platforms [63–65].”
Roux, C. (2018) · theses.fr (ABES) · doi:10.70675/d6ac8d0az8227z4463zb0c5z74a382a84245 · Cited by 1
Tamimi, R., Tafazzoli‐Shadpour, M., & Vosough, M. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189626 · Cited by 2
The effect of mesenchymal stem cells in rheumatoid arthritis: A systematic review
Prabowo, N. A., Nurudhin, A., Werdiningsih, Y., & Putri, D. P. (2026) · AIP conference proceedings · doi:10.1063/5.0341805
Mesenchymal Stem Cell‐Based Therapy for Cerebellar Ataxia: From Bench to Bedside
Suk, K., Lee, H., & Kim, S. R. (2026) · CNS Neuroscience & Therapeutics · doi:10.1002/cns.71038
“IDO-mediated T-cell suppression provides an additional immunomodulatory layer [39].”
Promises and Perspectives of Mesenchymal Stromal Cells in Companion and Farm Animals
Talluri, T. R., Nag, P., Rathore, N. S., Kues, W. A., Kumar, D., Selokar, N. L., Bajwa, K. K., Ansari, M. M., & Bhattacharya, T. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27187978
“PGE 2 , transforming growth factor-β 1 (TGF-β 1), PD-L1/programmed death ligand-2 (PD-L2), galectins, and other mediators can further reduce T-cell proliferation, inflammatory cytokine production, and cytotoxic activity [7,12,60,66].”
InfluentialLeavens, C. M., Chamberlain, C. S., Kapadia, D., Jurrens, N., Estrada, E. J., Talerico, K., Arroyo, M., -, P. D., & Odorico, J. S. (2026) · Regenerative Medicine · doi:10.1080/17460751.2026.2751695
Al-issawi, M. M., Gabr, M. M., Khater, S. M., & Abdel-Aziz, A.-A. (2025) · Reports of Biochemistry and Molecular Biology · doi:10.66224/rbmb.14.2.155
Metadata
- Authors
- Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J.
- Affiliations
- Emory University (US)
- Corresponding author
- Chinnadurai, Raghavan
- Galipeau, Jacques
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2014-02
- Volume
- 192
- Issue
- 4
- Pages
- 1491-1501
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2147854121
- Cited by
- 266
- References
- 63
- Citations by year
- 2026: 7 · 2025: 19 · 2024: 15 · 2023: 30 · 2022: 15 · 2021: 28 · 2020: 31 · 2019: 19 · 2018: 22 · 2017: 25 · 2016: 24 · 2015: 21 · 2014: 10
- FWCI
- 13.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (T32AI007610)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- mesenchymal stem cells, T cell effector function, PD-L1, PD-1, T cell degranulation, interleukin-2, T cell proliferation inhibition, bone marrow-derived stromal cells
- MeSH terms
- Bone Marrow Cells, Cells, Cultured, Humans, Interferon-gamma, Interleukin-2, Lymphocyte Activation, Tumor Necrosis Factor-alpha, Cell Degranulation, Th1 Cells, RNA Interference, RNA, Small Interfering, Cell Proliferation, Indoleamine-Pyrrole 2,3,-Dioxygenase, Mesenchymal Stem Cells, B7-H1 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.